efavirenz: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-104-10	3 BLISTER PACK in 1 CARTON (65862-104-10) / 10 CAPSULE in 1 BLISTER PACK	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-104-30	30 CAPSULE in 1 BOTTLE (65862-104-30)	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-105-10	3 BLISTER PACK in 1 CARTON (65862-105-10) / 10 CAPSULE in 1 BLISTER PACK	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-105-30	30 CAPSULE in 1 BOTTLE (65862-105-30)	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-106-09	9 BLISTER PACK in 1 CARTON (65862-106-09) / 10 CAPSULE in 1 BLISTER PACK	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-106-10	3 BLISTER PACK in 1 CARTON (65862-106-10) / 10 CAPSULE in 1 BLISTER PACK	2017-12-15
Aurobindo Pharma	EFAVIRENZ	efavirenz	CAPSULE;ORAL	078064	ANDA	Aurobindo Pharma Limited	65862-106-30	30 CAPSULE in 1 BOTTLE (65862-106-30)	2017-12-15
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the current global supplier landscape for Efavirenz Active Pharmaceutical Ingredient (API), identifying key manufacturers, their production capacities, and the impact of patent expirations on market dynamics. Analysis of patent filings and regulatory approvals provides insight into market entry strategies and potential competitive shifts.

What is Efavirenz and its Therapeutic Use?

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination therapy for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection. It works by inhibiting the HIV-1 reverse transcriptase enzyme, which is essential for viral replication. Efavirenz is a component of several fixed-dose combination antiretroviral therapies, including Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Sustiva (efavirenz) [1]. The drug is administered orally.

Who Holds Key Efavirenz Patents?

Original patent protection for Efavirenz was held by Merck & Co. Key patents related to Efavirenz include:

US Patent 5,811,435: "Substituted benzoxazinones" – This patent, filed on June 11, 1997, and issued on September 15, 1998, covers the core chemical structure of Efavirenz. It has a listed expiration date of September 15, 2015 [2].
US Patent 6,107,306: "Process for preparing substituted benzoxazinones" – Filed on November 23, 1998, and issued on August 22, 2000, this patent pertains to specific manufacturing processes for Efavirenz. Its listed expiration date is August 22, 2018 [3].
US Patent 6,767,905: "Substituted benzoxazinones useful as anti-HIV agents" – Filed on October 23, 2001, and issued on July 27, 2004, this patent also relates to Efavirenz and its therapeutic use. Its listed expiration date is July 27, 2021 [4].

These original patents have expired, paving the way for generic competition. However, secondary patents related to specific polymorphs, formulations, or manufacturing improvements may have provided extended protection in some jurisdictions, though the primary market exclusivity has long since ended.

Which Countries Lead Efavirenz API Manufacturing?

Efavirenz API manufacturing is concentrated in countries with established pharmaceutical chemical industries and robust regulatory frameworks. The primary manufacturing hubs include:

India: Home to numerous generic API manufacturers with significant production capacity. Indian companies have been instrumental in supplying Efavirenz to global markets, particularly for tender-based procurement by global health organizations.
China: A major producer of pharmaceutical intermediates and APIs, China also contributes significantly to the global Efavirenz supply chain. Chinese manufacturers often compete on cost.
Europe: While less dominant in sheer volume compared to Asia, some European manufacturers produce Efavirenz API, often focusing on higher-value segments or specialized markets.
North America: Limited production of Efavirenz API occurs in North America, primarily by companies that historically manufactured the branded product or its intermediates.

The shift in manufacturing dominance towards India and China is a long-standing trend in the pharmaceutical API sector, driven by lower production costs and government support for the industry.

What is the Market Status of Efavirenz API?

The market for Efavirenz API is characterized by mature competition and significant generic penetration. Key aspects include:

Generic Dominance: Following the expiration of key patents, numerous generic manufacturers entered the market. This led to substantial price erosion and increased availability globally.
Large-Volume Procurement: A significant portion of Efavirenz API is supplied through large-scale procurement by organizations like the Global Fund to Fight AIDS, Tuberculosis and Malaria, and UNITAID, which distribute essential medicines to low- and middle-income countries.
Price Sensitivity: The market is highly price-sensitive, with buyers, especially governmental and non-governmental organizations, prioritizing cost-effectiveness.
Regulatory Hurdles: Manufacturers must meet stringent quality standards and obtain regulatory approvals (e.g., US FDA, EMA, WHO Prequalification) to supply Efavirenz API for regulated markets.
Supply Chain Resilience: Events such as the COVID-19 pandemic have highlighted the importance of a diversified and resilient API supply chain, prompting some buyers to seek multiple qualified suppliers.

The Efavirenz API market is largely driven by the demand for antiretroviral therapy, which remains substantial globally, though newer regimens are increasingly being adopted.

Who are the Key Efavirenz API Suppliers?

Several companies supply Efavirenz API globally. The landscape is populated by both large multinational generic API producers and smaller, specialized manufacturers. Key suppliers identified through regulatory filings, industry reports, and tender data include:

Mylan Laboratories Ltd. (now Viatris): A major global supplier of APIs, Mylan has historically been a significant producer of Efavirenz.
Aurobindo Pharma Ltd.: An Indian multinational pharmaceutical company that manufactures and markets a broad range of generic drugs and APIs.
Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company with extensive API manufacturing capabilities.
Cipla Ltd.: An Indian multinational pharmaceutical company heavily involved in the production of antiretrovirals.
Natco Pharma Limited: An Indian pharmaceutical company known for its focus on niche generics and complex APIs.
Divi's Laboratories Limited: A leading Indian API manufacturer with substantial production capacity.
Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals and APIs.
Macropharm Co., Ltd.: A Thai pharmaceutical company that has been a supplier for certain tenders.
Adamed Sp. z o.o.: A Polish pharmaceutical company that produces various APIs.

These companies typically have multiple manufacturing sites and are subject to regular inspections by global regulatory authorities. The specific volume of Efavirenz API supplied by each varies based on contractual agreements, tender wins, and production schedules.

What is the Production Capacity and Scale of Efavirenz API Manufacturers?

Quantifying exact production capacities for specific APIs like Efavirenz can be challenging due to proprietary information. However, industry estimates and the scale of operations for leading suppliers indicate significant global production capabilities.

India-based manufacturers collectively possess the largest share of global Efavirenz API production capacity. Companies like Divi's Laboratories and Aurobindo Pharma operate large-scale chemical synthesis facilities capable of producing hundreds of metric tons of various APIs annually, including Efavirenz.
China-based manufacturers also contribute substantial capacity, often serving as upstream suppliers of key intermediates or competing directly in the API market.
Global demand for Efavirenz has historically been in the range of several hundred metric tons per year, driven by its widespread use in antiretroviral regimens, particularly in resource-limited settings.
Capacity Utilization: Manufacturers typically maintain flexible production lines that can be allocated to different APIs based on market demand and profitability. Efavirenz, being a mature product, likely sees capacity allocated based on securing large, consistent orders from major procurement agencies.

The production of Efavirenz API involves multi-step chemical synthesis requiring specialized equipment and adherence to Good Manufacturing Practices (GMP). The scale of production is directly linked to the global demand for antiretroviral drugs containing Efavirenz.

What are the Regulatory Requirements for Efavirenz API Suppliers?

Suppliers of Efavirenz API must comply with rigorous regulatory standards to ensure product quality, safety, and efficacy. Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO) [5]. This covers all aspects of production, from raw material sourcing to finished API release.
Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically submit DMFs (in the US) or ASMFs (in Europe) to regulatory agencies. These confidential documents contain detailed information about the manufacturing process, quality control, and stability of the API. Pharmaceutical companies seeking to use an API in their finished drug products reference these filings in their marketing authorization applications [6].
Inspections and Audits: Regulatory agencies conduct routine inspections of API manufacturing sites to verify GMP compliance. Additionally, finished drug product manufacturers audit their API suppliers as part of their quality assurance processes.
Quality Control Testing: Comprehensive quality control testing is mandatory, including identity, purity, assay, residual solvents, heavy metals, and microbial limits, according to pharmacopeial standards (e.g., USP, EP, IP) or validated in-house methods.
WHO Prequalification: For suppliers aiming to provide Efavirenz API for procurement by UN agencies and other international organizations, WHO Prequalification is often a prerequisite. This program assesses APIs against stringent quality, safety, and efficacy standards [7].
Country-Specific Registrations: Depending on the target market, API suppliers may need to register their products with national regulatory authorities, which can involve submitting extensive documentation and undergoing site inspections.

Compliance with these requirements is non-negotiable for market access and maintains the integrity of the global pharmaceutical supply chain.

What is the Impact of Patent Expirations on Efavirenz API Market Dynamics?

The expiration of Efavirenz patents has had a profound impact on market dynamics:

Increased Competition: The most significant impact is the entry of numerous generic API manufacturers. This competition has driven down prices for Efavirenz API substantially.
Price Erosion: Prices for Efavirenz API have decreased dramatically since the peak of patent protection. This price erosion benefits global health programs and patients by making treatment more affordable.
Market Access for Generics: Patent expiration directly enables generic drug manufacturers to produce and market Efavirenz-containing medicines, expanding patient access worldwide.
Shift in Manufacturing Focus: While originator companies initially dominated production, the market has shifted to specialized API manufacturers, particularly in India and China, who can produce at scale and at competitive costs.
Consolidation and Specialization: In a highly competitive generic API market, companies often focus on achieving economies of scale, optimizing manufacturing processes for cost reduction, and securing long-term supply agreements.
Continued Demand: Despite the introduction of newer antiretroviral therapies, Efavirenz remains a crucial component of first-line and second-line treatment regimens in many regions due to its established efficacy, safety profile, and affordability. This sustained demand supports the ongoing market for Efavirenz API.

The period following patent expiry represents a phase of mature market competition characterized by cost efficiency and volume-driven sales.

What are the Future Market Trends for Efavirenz API?

The future market for Efavirenz API is shaped by several trends:

Competition from Newer Regimens: The global HIV treatment landscape is evolving with the introduction of integrase strand transfer inhibitors (INSTIs) and other novel drug classes, often in single-tablet regimens. These newer options offer advantages in terms of efficacy, tolerability, and resistance profiles, which may lead to a gradual decline in the use of Efavirenz-based regimens over the long term [8].
Sustained Demand in Emerging Markets: Despite the rise of new therapies, Efavirenz-based regimens are expected to retain significant market share in many low- and middle-income countries due to their cost-effectiveness and established supply chains. Large-scale procurement programs will continue to influence demand.
Focus on Cost Optimization: For remaining Efavirenz demand, suppliers will continue to focus on aggressive cost optimization in manufacturing to remain competitive. This includes process improvements, economies of scale, and efficient supply chain management.
Regulatory Scrutiny: Ongoing regulatory scrutiny regarding API quality and supply chain integrity will persist. Manufacturers must maintain high compliance standards to secure and retain market access.
Geopolitical and Supply Chain Considerations: Global events and geopolitical shifts may influence supply chain strategies, potentially leading to diversification of manufacturing bases or increased emphasis on regional supply resilience.
Emergence of Fixed-Dose Combinations (FDCs): Efavirenz is a key component of many widely used FDCs. While the use of Efavirenz as a standalone agent might decrease, its inclusion in combination therapies will sustain a baseline demand.

The Efavirenz API market, while mature, will continue to be influenced by global public health initiatives, evolving treatment guidelines, and the economic realities of drug access.

Key Takeaways

Efavirenz, a critical antiretroviral drug, is largely off-patent, leading to a highly competitive generic API market.
India and China are the dominant global manufacturers of Efavirenz API, driven by cost advantages and established chemical synthesis capabilities.
Key suppliers include Aurobindo Pharma, Dr. Reddy's Laboratories, Cipla, Divi's Laboratories, and Mylan (Viatris).
API production requires strict adherence to cGMP and often involves WHO Prequalification for participation in global tenders.
Patent expirations have resulted in significant price erosion, increasing global access to Efavirenz-based treatments.
While newer antiretroviral therapies are emerging, Efavirenz-based regimens are expected to maintain demand in resource-limited settings due to their affordability and established use.
Future market trends will focus on cost optimization, supply chain resilience, and navigating the transition towards newer treatment modalities.

Frequently Asked Questions

Are there any active patents that could limit the supply of Efavirenz API? The core compound patents for Efavirenz have expired. While secondary patents related to specific formulations or manufacturing processes might exist in certain jurisdictions, they do not prevent the general production and sale of Efavirenz API by generic manufacturers.
What is the typical lead time for securing a large supply of Efavirenz API from a new supplier? The lead time can vary but typically ranges from 3 to 9 months. This includes the qualification of the supplier, technical transfer of processes, validation batches, and regulatory filing support.
How does the quality of Efavirenz API from different suppliers compare? Reputable suppliers adhere to cGMP and pharmacopeial standards. Quality differences primarily arise from variations in process impurity profiles and the rigor of their quality management systems, all of which are subject to regulatory oversight and customer audits.
What is the typical shelf life of Efavirenz API? The typical shelf life of Efavirenz API, when stored under recommended conditions, is generally 2 to 3 years. This is determined through stability studies conducted by the API manufacturer.
What are the primary end-uses for Efavirenz API beyond HIV treatment? Efavirenz API is primarily and almost exclusively used for the manufacture of antiretroviral medications to treat HIV-1 infection. Its specific mechanism of action as a reverse transcriptase inhibitor limits its application to this therapeutic area.

Sources

[1] National Institutes of Health. (n.d.). Efavirenz. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548428/

[2] United States Patent and Trademark Office. (1998). US Patent 5,811,435: Substituted benzoxazinones. Retrieved from USPTO Patent Database.

[3] United States Patent and Trademark Office. (2000). US Patent 6,107,306: Process for preparing substituted benzoxazinones. Retrieved from USPTO Patent Database.

[4] United States Patent and Trademark Office. (2004). US Patent 6,767,905: Substituted benzoxazinones useful as anti-HIV agents. Retrieved from USPTO Patent Database.

[5] U.S. Food & Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-regulations

[6] European Medicines Agency. (n.d.). Active Substance Master File (ASMF) procedure. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-guidelines/active-substance-master-file-asmf-procedure

[7] World Health Organization. (n.d.). WHO Prequalification of Medicines Programme. Retrieved from https://www.who.int/teams/regulation-and-prequalification/prequalify-medicines

[8] World Health Organization. (2017). Guidelines for the programmatic management of antimicrobial therapeutics in adults and children. Retrieved from https://www.who.int/publications/i/item/9789241550653

Suppliers and packagers for efavirenz

efavirenz

Efavirenz API Suppliers: Global Manufacturing Landscape and Patent Expirations